Oxi Maker Receive Patent For Drug to Treat Opioid Addiction

oxi purdue pharma

Oxi Makers Receives Patent For Drug to Treat Opioid Addiciton

Purdue Pharma, the producer of OxyContin, has gotten a patent intended to treat the opioid addiction their medicine is helping to cause.

The patent, is for a new type of buprenorphine also know as the notorious Suboxone which so say is just as bad as opioids if not worse. These types of non-opioids are typically given and change the patients body chemistry.

Buprenorphine is right now recommended in tablets or quick dissolving strips. The patent is for a “wafer” of buprenorphine that would break down in only a couple of moments in water.

Purdue Pharma is the subject of numerous legal claims for supposedly powering the opioid problem. The Sackler family, which controls Purdue, was by and by named in a claim in June in which the Massachusetts lawyer general blamed them for a “savage, tricky plan to offer opioids.” The organization, and the Sackler family, deny those assertions.

Richard Slacker, a board member of Purdue Pharma is listed as one of the inventors of the new Buprenorphine patent.

The heavy use of OxyContin was powered by a campaign that financially compensated doctors for prescribing the pill, turning it into the most broadly recommended opioid. In spite of the fact. Oxy gathered more than $2 billion in sales in 2015, as indicated by the Los Angeles Times.

Purdue in 2007 lied about OxyContin’s potential addiction and paid a fine of $600 million because of it.

Not long ago, the organization gave $3.4 million to a charitable medication engineer chipping away at an over-the-counter form of naloxone, a nasal shower used to treat opioid overdoses that retails for about $140 per shot.

Around 48,000 individuals passed on from opioid overdoses a year ago, as indicated by the CDC. Since 2013, an aggregate of in excess of 170,000 individuals have passed on from overdosing on opioids, including heroin.

A Purdue representative declined to answer inquiries concerning the patent, calling the FT report “a story based on hypothesis.”

Oxi Makers Receives Patent For Drug to Treat Opioid Addiciton



Leave a Comment